Asthma Disparities and Differential Responses to Therapy

Price: FREE for members and non-members
Session recorded on December 4, 2019
Speaker: LeRoy Graham, MD, FCCP
Viewers can earn credit by completing the post test questions.

Asthma Disparities persist most notably among minorities, children and the poor. Many providers are unaware of these disparities and thereby ill prepared to recognize and address these disparities. Additionally, responses to asthma therapy may vary among certain high risk groups. Such differential response must be noted and inform effective  management strategies.

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no commercial support for this activity.

Target Audience

Primary Care Physicians and Fellows-in-Training

Learning Objectives

After viewing the video recording learners should be able to:
- Recognize asthma disparities among high risk groups
- Identify and utilize effective asthma therapy in high risk patient groups
- Utilize actionable community partnerships to address asthma disparities


Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.


Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.


Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Michael Blaiss, MD, Planner
Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare

Leroy Graham, MD, Speaker
Speaker/Honoraria: Teva, Integrity CE, ThermoFisher
Co-chair/Advisory Board: Sanofi/Gemzyme




Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.